|
| 34584159 | Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells. | Sci Rep | 2021 |
| 31964784 | CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies. | Clin Cancer Res | 2020 |
| 23575268 | Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. | MAbs | 2013 |
| 21881594 | Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. | Genes Immun | 2012 |
| 22750228 | Targeting the junction of CÉ¿mX and É¿-migis for the specific depletion of mIgE-expressing B cells. | Mol Immunol | 2012 |
| 22864384 | Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. | MAbs | 2012 |
| 20971830 | IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodeling of the airways. | Am J Respir Crit Care Med | 2011 |
| 21803750 | Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. | Ann Rheum Dis | 2011 |
| 21902688 | A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. | Br J Haematol | 2011 |
| 20042593 | Cell type-specific recognition of human metapneumoviruses (HMPVs) by retinoic acid-inducible gene I (RIG-I) and TLR7 and viral interference of RIG-I ligand recognition by HMPV-B1 phosphoprotein. | J Immunol | 2010 |
| 20843364 | Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. | Respir Res | 2010 |
| 20513525 | MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. | J Allergy Clin Immunol | 2010 |
| 20513521 | Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. | J Allergy Clin Immunol | 2010 |
| 20619294 | Prophylactic and therapeutic benefits of a monoclonal antibody against the fusion protein of human metapneumovirus in a mouse model. | Antiviral Res | 2010 |
| 18835037 | Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. | Leuk Res | 2009 |
| 20948567 | Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus. | Hum Genomics Proteomics | 2009 |
| 19699208 | The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. | J Mol Biol | 2009 |
| 19342971 | Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA. | J Immunother | 2009 |
| 19484140 | Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. | Neoplasia | 2009 |
| 19479852 | Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. | Arthritis Rheum | 2009 |
| 19568280 | An audience with...Peter Kiener. | Nat Rev Drug Discov | 2009 |
| 17990791 | Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. | Curr Top Microbiol Immunol | 2008 |
| 18802121 | YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. | J Immunol | 2008 |
| 19010911 | A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. | Cancer Res | 2008 |
| 19008400 | Identification of antibody neutralization epitopes on the fusion protein of human metapneumovirus. | J Gen Virol | 2008 |
| 18980502 | Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. | J Infect Dis | 2008 |
| 18475307 | Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha. | Mol Med | 2008 |
| 18648529 | Type I interferon: potential therapeutic target for psoriasis? | PLoS One | 2008 |
| 18389897 | The prophylactic administration of a monoclonal antibody against human metapneumovirus attenuates viral disease and airways hyperresponsiveness in mice. | Antivir Ther | 2008 |
| 17417641 | Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. | Nat Immunol | 2007 |
| 17968926 | Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. | Arthritis Rheum | 2007 |
| 17961258 | Motavizumab, a neutralizing anti-Respiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. | Virol J | 2007 |
| 18003958 | A chitinase-like protein in the lung and circulation of patients with severe asthma. | N Engl J Med | 2007 |
| 18049331 | Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. | J Immunother | 2007 |
| 17362988 | Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. | J Mol Biol | 2007 |
| 17440108 | Selective targeting and potent control of tumor growth using an EphA2/CD3-Bispecific single-chain antibody construct. | Cancer Res | 2007 |
| 16873237 | Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. | J Virol | 2006 |
| 17172415 | Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. | Mol Cancer Ther | 2006 |
| 16800841 | Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma. | Eur J Haematol | 2006 |
| 16793771 | Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). | J Biol Chem | 2006 |
| 15907931 | Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. | J Mol Biol | 2005 |
| 16251314 | Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. | Antimicrob Agents Chemother | 2005 |
| 15061197 | Alterations in Fas (CD 95/Apo-1) and Fas ligand (CD178) expression in acute promyelocytic leukemia during treatment with ATRA. | Leuk Lymphoma | 2004 |
| 15302161 | Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies. | Mol Immunol | 2004 |
| 15297418 | EphA2 expression is associated with aggressive features in ovarian carcinoma. | Clin Cancer Res | 2004 |
| 14977833 | PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. | Clin Cancer Res | 2004 |
| 15125967 | Identification of purine inhibitors of phosphodiesterase 7 (PDE7). | Bioorg Med Chem Lett | 2004 |
| 15101715 | Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome. | Leuk Lymphoma | 2004 |
| 12747783 | Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. | J Med Chem | 2003 |
| 14633720 | Differential EphA2 epitope display on normal versus malignant cells. | Cancer Res | 2003 |